Buy & Sell Valero Energy Corporation (VLO) – Valero Energy Corporation Price Today
Aura AI Summary
Key Stats
- $70.17BMarket Cap
- EnergySector
- -12.06%3M Drawdown
- $75.92BEnterprise Value
- 2.03%Dividend Yield
- 79% Buy | 21% SellTrading Activity
- 56 daysTypical Hold Time
Valero Energy Corporation (VLO) is currently valued at a market capitalization of $70.17B, with an enterprise value of $75.92B. Over the past 52 weeks, Valero Energy Corporation has traded between a low of $131.77 and a high of $262.62, highlighting its annual price range. Over the past three months, Valero Energy Corporation has recorded a drawdown of -12.06%, reflecting recent price volatility. Valero Energy Corporation offers a dividend yield of 2.03%, with the most recent dividend of $1.20 paid on 21 May 26. On average, investors hold Valero Energy Corporation for approximately 56 days, indicating typical investor behavior on the platform.
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Most Recent News
EU approves Cenrifki as first drug targeting disability progression in secondary progressive multiple sclerosis without relapses
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...

EU approves Sanofi's Cenrifki for secondary progressive multiple sclerosis without relapses
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...

Signify unveils strategy to boost focus, performance, and shareholder value by 2029.
Signify announced a new strategy at its 2026 Capital Markets Day to become a more focused and better-performing company by 2029. The plan includes prioritizing growth in connected lighting and consumer segments while optimizing less profitable areas....
